Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases
| Autor: | Cristian Lolli, Antonio Verde, Luca Degli Esposti, Valentina Acciai, Alessia Brigido, Emanuela Proietti, Sarah Scagliarini |
|---|---|
| Jazyk: | English<br />Spanish; Castilian<br />Italian |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2284-2403 2283-5733 |
| DOI: | 10.33393/grhta.2024.2892 |
| Popis: | Background: Cabozantinib use in everyday clinical practice for advanced or metastatic renal cell carcinoma (RCC) is relatively recent, and real-world data on treatment persistence, adherence and sequencing are still limited. Methods: We conducted an analysis based on an integrated administrative database, covering around 6.9 million health-assisted Italian individuals, to explore the use of cabozantinib for RCC. Patients with at least one prescription for cabozantinib during 2017-2020 were searched. These were characterized during all available period (i.e. from 2010 onwards) before the index date and were observed after inclusion. Results: A total of 113 patients treated with cabozantinib in second or subsequent line were included, and their demographic, clinical and treatment characteristics were described. About half of these RCC patients were aged >65 years (47.8%). Sixty patients (53.1%) were highly adherent to cabozantinib therapy, and the median cabozantinib treatment duration of use was 8.7 months (95% confidence interval: 5.8-11.1). During the first year of follow-up, the average total cost per patient was €32,508. Conclusions: We described second or subsequent line cabozantinib treatment for RCC in a real-world setting and the economic burden of disease in Italy, taking advantage of large, integrated administrative databases. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|